JP2021526017A5 - - Google Patents

Info

Publication number
JP2021526017A5
JP2021526017A5 JP2020565430A JP2020565430A JP2021526017A5 JP 2021526017 A5 JP2021526017 A5 JP 2021526017A5 JP 2020565430 A JP2020565430 A JP 2020565430A JP 2020565430 A JP2020565430 A JP 2020565430A JP 2021526017 A5 JP2021526017 A5 JP 2021526017A5
Authority
JP
Japan
Prior art keywords
exon
pharmaceutically acceptable
subject
antisense oligomer
acceptable salt
Prior art date
Application number
JP2020565430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021526017A (ja
JP7370344B2 (ja
JPWO2019231824A5 (https=
Filing date
Publication date
Priority claimed from US15/993,267 external-priority patent/US10758629B2/en
Application filed filed Critical
Publication of JP2021526017A publication Critical patent/JP2021526017A/ja
Publication of JP2021526017A5 publication Critical patent/JP2021526017A5/ja
Publication of JPWO2019231824A5 publication Critical patent/JPWO2019231824A5/ja
Application granted granted Critical
Publication of JP7370344B2 publication Critical patent/JP7370344B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020565430A 2018-05-29 2019-05-23 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート Active JP7370344B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862677484P 2018-05-29 2018-05-29
US62/677,484 2018-05-29
US15/993,287 2018-05-30
US15/993,267 2018-05-30
US15/993,267 US10758629B2 (en) 2018-05-29 2018-05-30 Exon skipping oligomer conjugates for muscular dystrophy
US15/993,287 US10765760B2 (en) 2018-05-29 2018-05-30 Exon skipping oligomer conjugates for muscular dystrophy
PCT/US2019/033768 WO2019231824A1 (en) 2018-05-29 2019-05-23 Exon skipping oligomer conjugates for muscular dystrophy

Publications (4)

Publication Number Publication Date
JP2021526017A JP2021526017A (ja) 2021-09-30
JP2021526017A5 true JP2021526017A5 (https=) 2022-05-24
JPWO2019231824A5 JPWO2019231824A5 (https=) 2022-05-24
JP7370344B2 JP7370344B2 (ja) 2023-10-27

Family

ID=68694919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020565430A Active JP7370344B2 (ja) 2018-05-29 2019-05-23 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート

Country Status (18)

Country Link
US (6) US10758629B2 (https=)
EP (1) EP3801544A4 (https=)
JP (1) JP7370344B2 (https=)
KR (2) KR102904499B1 (https=)
CN (1) CN112384222B (https=)
AR (1) AR117587A1 (https=)
AU (1) AU2019276995B2 (https=)
BR (1) BR112020024349A2 (https=)
CA (1) CA3101228A1 (https=)
CL (1) CL2020003030A1 (https=)
EA (1) EA202092772A1 (https=)
IL (1) IL278966B2 (https=)
MA (1) MA52801A (https=)
MX (1) MX2020012645A (https=)
SA (1) SA520420562B1 (https=)
SG (1) SG11202010018UA (https=)
TW (1) TWI845511B (https=)
WO (1) WO2019231824A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10758629B2 (en) 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP3955966A1 (en) * 2019-04-18 2022-02-23 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
US20230020092A1 (en) 2019-12-19 2023-01-19 Entrada Therapeutics, Inc. Compositions for delivery of antisense compounds
WO2021174036A1 (en) * 2020-02-28 2021-09-02 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating scn1a expression
US20250243244A1 (en) 2021-03-31 2025-07-31 Entrada Therapeutics, Inc. Cyclic cell penetrating peptides
US20240358845A1 (en) 2021-05-10 2024-10-31 Entrada Therapeutics, Inc. Compositions and methods for intracellular therapeutics
US12378267B2 (en) 2021-06-17 2025-08-05 Entrada Therapeutics, Inc. Synthesis of FMOC-protected morpholino monomers and oligomers
US20250289851A1 (en) 2022-04-22 2025-09-18 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics
EP4658280A2 (en) * 2023-02-01 2025-12-10 Alnylam Pharmaceuticals, Inc. Six membered ring containing oligomers
CN120648680A (zh) * 2024-03-15 2025-09-16 迦进生物医药(上海)有限公司 治疗杜兴型肌营养不良症和贝克型肌营养不良症的药物
WO2026080471A2 (en) 2024-10-07 2026-04-16 Flagship Pioneering Innovations Vi, Llc Compositions of trem conjugates and uses thereof

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
JP3022967B2 (ja) 1985-03-15 2000-03-21 アンチバイラルズ インコーポレイテッド 立体規則性ポリヌクレオチド結合ポリマー
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
CN1123038A (zh) 1993-05-11 1996-05-22 北卡罗来纳大学查珀尔希尔分校 阻止异常剪接的反义寡核苷酸及其使用方法
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
WO1999042091A2 (en) 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
US6683173B2 (en) 1998-04-03 2004-01-27 Epoch Biosciences, Inc. Tm leveling methods
US6210892B1 (en) 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
JP2000125448A (ja) 1998-10-14 2000-04-28 Yazaki Corp 電気接続箱
JP2000256547A (ja) 1999-03-10 2000-09-19 Sumitomo Dow Ltd 耐熱性プラスチックカード用樹脂組成物
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
EP1178999B1 (en) 1999-05-04 2007-03-14 Santaris Pharma A/S L-ribo-lna analogues
JP2000325085A (ja) 1999-05-21 2000-11-28 Masafumi Matsuo デュシェンヌ型筋ジストロフィー治療剤
US7070807B2 (en) 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
US7163695B2 (en) 1999-12-29 2007-01-16 Mixson A James Histidine copolymer and methods for using same
US6653467B1 (en) 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
US6727355B2 (en) 2000-08-25 2004-04-27 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of Duchenne muscular dystrophy
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
AU2002334307A1 (en) 2001-09-04 2003-03-18 Exiqon A/S Novel lna compositions and uses thereof
KR100464261B1 (ko) 2002-01-24 2005-01-03 주식회사 파나진 Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
KR20030084444A (ko) 2002-04-26 2003-11-01 주식회사 파나진 Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
WO2004043978A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
JP4777777B2 (ja) 2002-11-25 2011-09-21 雅文 松尾 mRNA前駆体のスプライシングを修飾するENA核酸医薬
CA2524255C (en) 2003-03-21 2014-02-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
US7211668B2 (en) 2003-07-28 2007-05-01 Panagene, Inc. PNA monomer and precursor
ATE498685T1 (de) 2004-06-28 2011-03-15 Univ Western Australia Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
NZ563206A (en) 2005-04-22 2009-09-25 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mRNA by interfering with the binding or SR proteins and by interfering with secondary RNA structure
KR101789603B1 (ko) 2005-11-10 2017-11-21 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Tnf 수퍼패밀리 수용체에 대한 스플라이스 스위칭올리고머 및 염증성 질환 치료용 약제학적 조성물
JP3151554U (ja) 2006-05-17 2009-07-02 スヴェトラナ アナトレフナ ソコロヴァ 輸送手段
JP5575486B2 (ja) 2007-01-18 2014-08-20 ユニヴァーシティ オブ ミズーリー−コロンビア 筋鞘にnNOSを回復させる合成ミニ/ミクロジストロフィン遺伝子
CA2693742A1 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
AU2008317566B2 (en) 2007-10-26 2014-05-01 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
MX2010004955A (es) 2007-11-15 2010-06-30 Avi Biopharma Inc Metodo de sintesis de oligomeros de morfolina.
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
CN112574988A (zh) * 2008-10-24 2021-03-30 萨雷普塔治疗公司 用于dmd的多外显子跳跃组合物
JP5786109B2 (ja) 2008-10-27 2015-09-30 プロセンサ テクノロジーズ ベー.フェー. Duchenne型筋ジストロフィーmRNA前駆体のエクソン45の効率的なスキッピングのための方法及び手段
RU2572826C2 (ru) 2008-12-02 2016-01-20 Чиралджен, Лтд. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
US20120149756A1 (en) 2009-04-10 2012-06-14 Associatin Institut de Myologie Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
CA2759899A1 (en) 2009-04-24 2010-10-28 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
EP2479182B8 (en) 2009-09-16 2016-07-13 Wave Life Sciences Japan, Inc. Novel protecting group for synthesizing rna and derivative thereof
LT2499249T (lt) * 2009-11-12 2018-12-27 The University Of Western Australia Priešprasmės molekulės ir patologijų gydymo būdai
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
EP2672977A1 (en) 2011-02-08 2013-12-18 The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System Antisense oligonucleotides
US9161948B2 (en) * 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
EP2581448B1 (en) 2011-10-13 2015-01-28 Association Institut de Myologie Tricyclo-phosphorothioate DNA
EA202090338A1 (ru) 2011-11-18 2021-04-30 Сарепта Терапьютикс, Инк. Функционально-модифицированные олигонуклеотиды и их субъединицы
CN117721110A (zh) 2011-12-28 2024-03-19 日本新药株式会社 反义核酸
CN112251436A (zh) 2012-01-27 2021-01-22 比奥马林技术公司 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
DE102012101676A1 (de) 2012-02-29 2013-08-29 Klaus-Dieter Rösler Verfahren und Vorrichtung zum Bearbeiten von Formularen mit einer Datenverarbeitungsanlage
EP2870246B1 (en) 2012-07-03 2019-09-11 BioMarin Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
JP6453212B2 (ja) 2012-07-13 2019-01-16 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. キラル制御
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
CA2894899A1 (en) 2012-12-20 2014-06-26 Sarepta Therapeutics, Inc. Improved exon skipping compositions for treating muscular dystrophy
NZ731587A (en) * 2013-03-14 2021-07-30 Sarepta Therapeutics Inc Exon skipping compositions for treating muscular dystrophy
RS58529B1 (sr) 2013-03-14 2019-04-30 Sarepta Therapeutics Inc Sastavi koji preskaču egzon za tretiranje mišićne distrofije
CA2906812A1 (en) * 2013-03-15 2014-09-18 Sarepta Therapeutics, Inc. Improved compositions for treating muscular dystrophy
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
SMT201900169T1 (it) 2014-03-12 2019-05-10 Nippon Shinyaku Co Ltd Acido nucleico antisenso
US9790495B2 (en) * 2014-05-16 2017-10-17 Oregon State University Antisense antibacterial compounds and methods
BR112016027236A2 (pt) * 2014-05-23 2017-10-17 Genzyme Corp porções de múltiplos oligonucleotídeos em veículo de peptídeo
RU2695430C2 (ru) 2014-06-17 2019-07-23 Ниппон Синяку Ко., Лтд. Антисмысловые нуклеиновые кислоты
AU2015338923B2 (en) 2014-11-02 2021-10-21 Arcturus Therapeutics, Inc. Messenger UNA molecules and uses thereof
CN108135921B (zh) 2015-07-22 2023-10-17 波涛生命科学有限公司 寡核苷酸组合物及其方法
US20180265859A1 (en) 2015-09-23 2018-09-20 UNIVERSITé LAVAL Modification of the dystrophin gene and uses thereof
EP3858993A1 (en) * 2015-10-09 2021-08-04 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
JP7511326B2 (ja) 2015-10-09 2024-07-05 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド組成物およびその方法
JP2019516680A (ja) 2016-05-04 2019-06-20 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. オリゴヌクレオチド組成物およびその方法
WO2017192679A1 (en) 2016-05-04 2017-11-09 Wave Life Sciences Ltd. Methods and compositions of biologically active agents
TW201811807A (zh) * 2016-06-30 2018-04-01 美商薩羅塔治療公司 用於肌肉萎縮症之外顯子跳躍寡聚物
IL297528A (en) 2016-12-19 2022-12-01 Sarepta Therapeutics Inc Exon-skipping oligomer conjugates for muscular dystrophy
US10758629B2 (en) 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
US11402658B2 (en) 2019-07-30 2022-08-02 General Scientific Corp. / Surgitel Removable, adjustable wire arms for nose pads

Similar Documents

Publication Publication Date Title
JP2021526017A5 (https=)
JP2020511943A5 (https=)
JP2020537501A5 (https=)
JP2020503010A5 (https=)
JP2020503009A5 (https=)
JP7792371B2 (ja) GalNAc誘導体
US20230302146A1 (en) Hybrid carriers for nucleic acid cargo
JP2021511038A5 (https=)
JP2021521794A5 (https=)
US20190381180A1 (en) Hybrid carriers for nucleic acid cargo
JP2021511312A5 (https=)
JP2018530560A5 (https=)
JP2012506703A5 (https=)
JP2019525918A5 (https=)
JP2018521970A (ja) ペプチドオリゴヌクレオチドコンジュゲート
US20210040483A1 (en) Modified oligonucleotides and methods of use
RU2006109491A (ru) Новые трициклические нуклеозиды или нуклеотиды в качестве терапевтических средств
JP2012505250A5 (https=)
JP2016533761A5 (https=)
US9062121B2 (en) Stabilized STAT3 decoy oligonucleotides and uses therefore
JPWO2019231824A5 (https=)
TW201907009A (zh) 用於治療b型肝炎之治療組成物及方法
JP2018506272A5 (https=)
JP2019527549A5 (https=)
IL318474A (en) Axon-skipping oligomer complexes for muscular dystrophy